Concepedia

Publication | Closed Access

Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26

DOI

222

Citations

24

References

2007

Year

Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya, Masanori Yoshino, Taishi Kuwahara, Hiroki Tsukada, Katsuya Fujimoto, Ikuyo Sato, Mikio Ueda, Masahide Horiba,
Clinical Infectious Diseases

Abstract

Genotype-based EFV dose reduction is feasible in CYP2B6 *6/*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms.

References

YearCitations

Page 1